Clinical Trial Update: Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesophageal Junction Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating sintilimab with bevacizumab and XELOX/SOX in initially unresectable AFP-positive gastric/GEJ adenocarcinoma; trial status is n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Capecitabine (capecitabine)
• OXALIPLATIN (Oxaliplatin)
• S-1 (tegafur/gimeracil/oteracil)
• Sintilimab (sintilimab)

Snippet

Sponsor: Fudan University | Conditions: Gastric Cancer (GC), AFP Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 2 | Status: NOT_YET_RECRUITING